I own KERX as well as many other biotechs.
I was way down on the stock ($1/share) but kept it anyway figuring I had lost all my $$, so what the hell.
I now have a nice profit...the company has long term potential but took a hit after FDA approval.
I also like TTPH and XNPT...
Hoping the best for CLDX.
I lost $$$ on DNDN.
Sentiment: Strong Buy
I hope you are wrong. I bought shares after Roskamp got into the act:
he basic science associated with anatabine citrate continues to be validated and expanded. As previously disclosed, abstracts outlining four separate preclinical studies evaluating anatabine were recently accepted for poster and nano symposium presentations at the upcoming annual meeting of the Society for Neuroscience, taking place November 15-19 in Washington, DC. The presentations specifically will focus on anatabine's beneficial activity in animal models of Traumatic Brain Injury, Gulf War Illness and Alzheimer's Disease. All of these studies were independently conducted and presented by the Roskamp Institute, a not-for-profit research organization devoted to understanding neurodegenerative diseases, disorders and addictions. The studies were funded by either the Roskamp Foundation or by awards through the Congressionally Directed Medical Research Program.
Researchers from the Roskamp Institute recently published a manuscript in "Brain Disorders & Therapy," May 2014, entitled "Anatabine Attenuates Tau Phosphorylation and Oligomerization in P301S Tau Transgenic Mice." The article described how anatabine attenuated tau phosphorylation in vivo animal models which included the molecular activation inhibition of GSK3b, STAT3 and NF-kb as a proposed mechanism of action.
Rock Creek Pharmaceuticals recently retained a major, national intellectual property advisory and investment bank, as a strategic advisor, to monitor, value and evaluate the growth of the Company's intellectual property (IP) portfolio. Concurrently, the Company continues to take measures to protect existing IP as well as enhancing and developing additional IP.
The Roskamp Institute here in Sarasota is highly regarded..why would they get involved with crooks?
.The only way they can remain on the board is to do a R/S. bummer.
Wow...I didn't think anyone was left from BioSante daysexcept me. I never sold my shares.
I just gave up and hoped for thie best. First time I have looked at this MB.
I had another stock INKP that went to almost nothing and got acquired by SLXP. the rest is nice history.
This company has legs. After all the splits I am only left with 47 shares but I'm almost at break even.
I wasn't so lucky with DNDN. Took a tax loss on that one today. GLTAL
Sentiment: Strong Buy
How do you know the volume that has been sold on Amazon? or anywhere else?
I am a recent stockholder and have not been able to find any info regarding product sales.
LAKE is very forthcoming with updates..
APT should hire a new Investor Relations person.
Myabe..but in the sort term this is the range we will stay in....unless someone decides to acquire the company.
I had sold my original shares too early last week and regretted it.
Bought most of those shares back this morning at $7.65...not selling this time...long term hold.
APT should have great earnings next year. Ebola is only one of many viruses we will have to contend with in the future. Hospitals etc will have to have a prevention protocol. My only concern is competition in this space..how long will it take for the Chinese to flood the market with cheaper goods?
For now, APT is a good investment.
Sentiment: Strong Buy
On the wires:
Sumitomo will set up a special investigation into how it lost nearly $1.8B in Texas shale oil and Australian coal mining, after writedowns connected to the investments almost completely wipe out its full-year earnings forecast.
Most of the losses were incurred at the shale oil project it shares with Devon Energy (NYSE:DVN); in 2012, Sumitomo paid DVN $340M for 30% of the project in the Permian Basin, agreeing to supply another $1B to fund most of the cost of drilling wells, but now it says it wants to sell most of its share since it is “difficult to extract the oil and gas efficiently."
The company also plans to stop production at the Isaac Plains coal mine in Australia's Queensland state it co-owns with Vale (NYSE:VALE) by the end of January.
“Even by the standards of trading companies, this is not good,” says the co-head of Japan equities at Mirabaud Securities, drawing parallels to Mitsui's costly exposure to BP’s blowout in the Gulf of Mexico.
I don't know how old you are, but I've been to this rodeo many times.
I agree with much of what you said.
Unfortunately, although the news is not "new", it is different from historical patterns.
I also feel many stock valuations are ridiculous. .
Yes, the MMs (and their machines) control the markets. It's an extremely hostile environment for retail investors.
The commodities will come back..it's just a matter of when.
My conception of a "long term Hold" has a shorter expiration date...just like me.
Brazil's real falls to a five-year low and Petrobras (PBR -11.1%) plunges more than 10% at the open after a new poll showed Pres. Rousseff widening her lead over opposition candidate Marina Silva.
The real dropped 2.1% in early trading, and the currency has tumbled 11% so far in Q3 with volatility increasing as the Oct. 5 presidential vote approaches.
Over the weekend, Rousseff rejected rumors of soliciting funds from PBR for her campaign in 2010.
ITUB -7.6%, BBD -6.8%, GOL -5.4%, GFA -4.8%, BRFS -3.7%, VALE -2.8%, TSU -2.4%, BSBR -2.1%, SID -1.8%, ERJ -1.6%.
Brazil ETFs: EWZ, BRF, BRXX, EWZS, BRAQ, BRZU, BRAZ, BZQ, BRAF, UBR, BRZS, DBBR, FBZ
~ck (very long)
I think the overall market correction will be in the near term.
Political problems worldwide, the strong dollar and debt will be the contibuting factors.
You can read stories about Adaptimmune which just entered a partnership with GSK.
I haven't researched GSK enought to comment.
I'll stick to Vale/CLF comments on this MB. I've found people get annoyed with OT posts.
Yes. I held my biotechs. I have invested in the sector for many years. Thye are risky investments but I have the stomach for the FDA failures. I've made big money and lost big money. My latest is TTPH. Too expensive now but I'm in at $10. I bought more during the sell off. I own over 20 companies..some are in the tank.
Sometimes it's about knowing when to sell. I owned KERX for many years..I road it way down to $2. Then things changed and before FDA approval for Zerenex it went to $18...after approval it is now at $14...
It's all about the management, science, possible partnering with pharma and cash burn.
I have an old friend who is a retired top chemist from MRK. He and I exchange
thoughts on biotech companies.
I bought some of the commodities many years ago when they tanked.and the market was in the crapper...companies like FCX etc.. I remember I bought when Mark Haines (R.I.P.)on CNBC said it was the bottom. I had great respect for his opinions and jumped in..My friends thought I was insane. I made some nice $$.
My mistake was getting back in a few years ago..my coal stocks are really really bad performers.
OK..too much coffee this morning.
TTPH presents today ar a Biotech Conference in NYC...2:30 PM.
Could be interesting.
This has been a great stock to own.
Sentiment: Strong Buy
I sold in the $10s around time of AMGN announcement and bought back today.
Hoping for the best.
I am more concerned about the overall market now that BABA hype is over.
Sentiment: Strong Buy
NEW YORK, Sept 18 (Reuters) - When Alibaba Group Holding Ltd begins trading on Friday the shares may not be able to avoid the kind of volatility typically seen in trading of eagerly anticipated IPOs, even as the bulk of the shares sold are expected to reside with 25 to 50 behemoth institutions.
Underwriters hope that allocating the majority of the Chinese e-commerce company's shares to institutional investors, thought of as being less likely than their retail counterparts to sell quickly, may prevent Aliba
The company is expected to sell about $22 billion in shares after the close of trading Thursday in what is expected to be one of the biggest IPOs in history.
"For this kind of large deal, it's very common to allocate the bulk of shares to the large institutionals who will hold it for the long run," said Josef Schuster, founder of Chicago-based IPOX Schuster LLC, which helps create index funds for IPOs.
Yet the line of fund managers who look set to dominate Alibaba's (Symbol : BABA
IPO does not guarantee investors will hang onto their shares for very long, especially if they do not get what they want out of the allocation, people watching the IPO said.
"The biggest pitfall is to ensure that the allocations stick," said one event-driven investor, who put in an order of shares, but did not want to be named.
Another complicating factor for Alibaba (Symbol : BABA
is that in addition to the 320 million shares being offered, there is an additional 128.4 million in shares - about 5 percent of overall outstanding shares - that are not subject to lock-up agreements that restrict insider sales shortly after an IPO, according to company filings.
That's unusual, and could add some additional selling pressure and increases the incentive for the company to make sure the long-term holders intend to keep their allocation.